Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.
Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.
Royalty Pharma plc executive Marshall Urist, EVP of Research & Investments, reported a planned sale of Class A Ordinary Shares through an affiliated entity. On January 23, 2026, 20,000 Class A Ordinary Shares were sold by Sandy Lamm LLC, an entity associated with Urist, at a weighted average price of $40.2555 per share under a pre-established Rule 10b5-1 trading plan adopted on September 16, 2025.
Following this transaction, the filing shows indirect ownership of 20,000 shares through Sandy Lamm LLC, 19,020 shares held indirectly via an IRA, and 7,398 shares held directly. The filing also notes additional exchangeable interests and Class E Ordinary Shares in affiliated Royalty Pharma entities that can convert into Royalty Pharma plc Class A Ordinary Shares, with some of those Class E shares subject to vesting conditions.
Royalty Pharma plc EVP & CFO Terrance P. Coyne reported automatic sales of Class A Ordinary Shares through entities associated with him. On January 20, 2026, TPC RP 2021, LLC sold 65,832 Class A shares at a weighted average price of $39.3484 per share, leaving 394,996 shares held indirectly by that LLC. On the same date, TPC RP EPA1 LLC sold 3,750 Class A shares at a weighted average price of $39.3484, with 36,010 shares remaining held indirectly by that LLC.
All reported sales were made under a Rule 10b5-1 trading plan adopted by Coyne on August 8, 2025, meaning they were pre-arranged. In addition, Coyne reports indirect holdings of Class A shares through a spouse’s IRA, his own IRA, and shares held by his spouse, as well as limited partnership and Class E Ordinary Share interests that are exchangeable for additional Class A Ordinary Shares, with some of those interests subject to vesting conditions.
Royalty Pharma EVP Marshall Urist, through Sandy Lamm LLC, sold 20,000 Class A Ordinary Shares of Royalty Pharma plc on January 16, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on September 16, 2025. The shares were sold at a weighted average price of $39.5173 in multiple trades between $39.37 and $39.76 per share. Following the sale, Sandy Lamm LLC held 40,000 shares, an IRA associated with the reporting person held 19,020 shares, and 7,398 shares were held directly. In addition, the reporting person and family vehicles hold limited partnership and holding company interests exchangeable into 2,474,120 and 1,356,528 Class A Ordinary Shares, with certain Class E shares subject to vesting conditions.
A holder of the issuer’s common stock has filed a Form 144 notice to sell 69,582 shares of common stock through Goldman Sachs & Co. LLC, with an aggregate market value of $2,719,960.38. The filing notes that there were 427,247,489 shares of this class outstanding and that the approximate sale date is January 20, 2026 on the NASD.
The shares to be sold were originally acquired from the issuer in 2020, including 65,832 shares in a private transaction on June 16, 2020 and 3,750 shares as compensation performance awards on February 12, 2020. The notice also lists prior sales over the past three months by entities such as TPC RP 2021 LLC and TPC RP EPA1 LLC, including blocks of 32,916 shares of common stock on various dates, with single transactions generating gross proceeds such as $1,277,555.54.
Royalty Pharma plc reported an insider transaction involving an entity affiliated with its EVP, Research & Investments, Marshall Urist. On January 9, 2026, Sandy Lamm LLC, an entity associated with Urist, sold 20,000 Class A Ordinary Shares at a weighted average price of $40.7817 per share pursuant to a Rule 10b5-1 trading plan adopted on September 16, 2025. After this sale, 60,000 Class A Ordinary Shares were held indirectly through Sandy Lamm LLC, 19,020 shares were held indirectly through an IRA, and 7,398 shares were held directly.
Royalty Pharma has a planned Rule 144 sale of 495860 shares of common stock through Goldman Sachs & Co. LLC, with an aggregate market value of 20523645.4 and 427247489 shares outstanding. The shares are expected to be sold on or about 01/07/2026 on NASD. They were originally acquired from the issuer in a private transaction on 06/16/2020, with 495860 shares received on that date.
Over the past 3 months, the person for whose account the securities are to be sold and related entities have already sold multiple blocks of common stock, including 3000 shares on 11/19/2025 for gross proceeds of 113364 and 110000 shares on 12/03/2025 for 4375008. Additional sales by entities such as GWL 2014 G LLC, GWL 2020 G LLC, GWL 2023 G HoldCo LLC, and GWL 2021 G LLC are also listed, reflecting an ongoing disposition program.
Royalty Pharma plc’s EVP & CFO Terrance P. Coyne reported indirect sales of Class A Ordinary Shares through entities associated with him. On January 2, 2026, TPC RP 2021, LLC sold 65,832 Class A shares and TPC RP EPA1 LLC sold 3,750 Class A shares, both at a weighted average price of $38.4157 per share, under a Rule 10b5-1 trading plan adopted on August 8, 2025.
After these trades, TPC RP 2021, LLC held 460,828 Class A shares and TPC RP EPA1 LLC held 39,760 Class A shares, reported as indirect holdings for Coyne. Additional indirect holdings include shares held through the reporting person’s and spouse’s IRAs and by the spouse, as well as partnership and Royalty Pharma Holdings Ltd interests exchangeable into 6,448,180 and 1,807,277 Class A shares, respectively, with the latter subject to vesting conditions.
Royalty Pharma plc executive Marshall Urist, EVP of Research & Investments, reported selling 20,000 Class A Ordinary Shares on December 16, 2025. The sale, coded as "S," was executed at a weighted average price of $38.321 per share, with individual trades ranging from $38.24 to $38.40. All transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 16, 2025.
Following this activity, Urist reports beneficial ownership of 140,000 Class A shares indirectly through Sandy Lamm LLC, 19,020 shares indirectly through an IRA, and 7,398 shares held directly. In addition, Urist and related family vehicles hold limited partnership interests exchangeable into 2,474,120 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into a further 1,356,528 Class A Ordinary Shares, with the Class E shares subject to vesting conditions.
Royalty Pharma plc executive vice president and chief financial officer Terrance P. Coyne reported selling Class A ordinary shares of Royalty Pharma plc on 12/15/2025 under a pre-arranged Rule 10b5-1 trading plan. The filing shows a sale of 65,832 Class A shares at a weighted average price of $38.3601 per share, with individual trades occurring between $38.10 and $38.48 per share.
After these transactions, Coyne continues to report indirect beneficial ownership of 526,660 Class A shares through TPC RP 2021, LLC and 43,510 Class A shares through TPC RP EPA1 LLC, along with additional holdings in IRA and spouse accounts. The remarks also state that entities controlled by him hold interests exchangeable into 6,448,180 Class A shares and Class E shares exchangeable into 1,807,277 Class A shares, with the Class E shares subject to vesting conditions.
Royalty Pharma plc (RPRX) EVP & CFO Terrance P. Coyne reported insider stock sales in a Form 4 filing. On 11/24/2025, multiple sales of Class A ordinary shares were executed, including 55,146 shares held indirectly through TPC RP 2021, LLC at a weighted average price of $38.6663 per share and 10,686 shares at a weighted average price of $37.9604 per share. Additional smaller sales were reported through TPC RP EPA1 LLC.
After these transactions, Coyne continues to hold significant indirect stakes, including 669,010 Class A ordinary shares via TPC RP 2021, LLC and 51,634 Class A ordinary shares via TPC RP EPA1 LLC, plus various IRA and spousal accounts. The filing also notes limited partnership interests exchangeable into 6,448,180 Class A ordinary shares and 1,807,277 Class E ordinary shares of Royalty Pharma Holdings Ltd, some of which are subject to vesting conditions. All reported sales were made under a Rule 10b5-1 trading plan adopted on August 8, 2025.